首页> 外文期刊>Frontiers in Chemistry >Status of Targeting MreB for the Development of Antibiotics
【24h】

Status of Targeting MreB for the Development of Antibiotics

机译:针对抗生素发展的伤害状态的地位

获取原文
           

摘要

Although many prospective antibiotic targets are known, bacterial infections and resistance to antibiotics remain a threat to public health partly because the druggable potentials of most of these targets have yet to be fully tapped for the development of a new generation of therapeutics. The prokaryotic actin homolog MreB is one of the important antibiotic targets that are yet to be significantly exploited. MreB is a bacterial cytoskeleton protein that has been widely studied and is associated with the determination of rod shape as well as important subcellular processes including cell division, chromosome segregation, cell wall morphogenesis, and cell polarity. Notwithstanding that MreB is vital and conserved in rod-shaped bacteria, no approved antibiotics targeting it are presently available. Here, the status of targeting MreB for the development of antibiotics is concisely summarized. Expressly, the known therapeutic targets and inhibitors of MreB are presented, and the way forward in the search for a new generation of potent inhibitors of MreB briefly discussed.
机译:尽管已知许多前瞻性抗生素靶标是已知的,但细菌感染和对抗生素的抗性仍然是对公共卫生的威胁,部分是因为大多数这些目标的可毒潜力尚未完全挖掘新一代治疗方法。原核actin homolog mreb是重要的抗生素目标之一,尚未显着剥削。 MREB是一种被广泛研究的细菌细胞骨架蛋白,并且与棒状的测定以及包括细胞分裂,染色体隔离,细胞壁形态发生和细胞极性的重要亚细胞过程相关。尽管MREB是至关重要的,并且在棒状细菌中保守,但目前没有批准的抗生素靶向。在此,简明扼要地综述了靶向抗生素的抗生素的状态。明智地,提出了已知的MREB治疗靶标和抑制剂,并在寻找新一代的MREB的新一代强度抑制剂的方式简要讨论过。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号